ArticleObesity pillars2026
Impact of treatment on healthcare resource utilization and cost of care among adults with obstructive sleep apnea and obesity.
Article in Obesity pillars, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Obstructive sleep apnea (OSA) disproportionately affects individuals with obesity and is associated with significant morbidity. The objective of this study was to estimate the cost of care and healthcare resource utilization among adults with OSA and obesity by OSA treatment status. Methods: This retrospective, longitudinal study used Optum's de-identified Market Clarity Data (Optum® Market Clarity) from Oct 2015 to Mar 2024. Adults (≥18 years old) with an OSA diagnosis, body mass index (BMI) ≥30 kg/m Results: The final sample included 10,116 individuals in the OSA-treated cohort and 3,881 individuals in the OSA-untreated cohort. In fully adjusted models, treated individuals had significantly lower least squares mean costs ($34,248 vs. $37,295, p = 0.0003) and had fewer acute care events, including emergency department (ED) visits and hospitalization days (0.87 vs. 1.09, p < 0.0001), compared to untreated individuals. They also had an 18% lower likelihood of ≥1 ED visit or day of hospitalization (odds ratio = 0.82; 95% confidence interval: 0.75, 0.89). Results were consistent across subgroups, including those with moderate-to-severe OSA and individuals with Medicare or commercial insurance. Conclusion: These findings suggest that receiving treatment for OSA significantly reduces overall healthcare utilization among individuals with OSA and obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.